Can-Fite Reports Financial Results for Nine Months Ended September 30, 2015

Significant developments with CF102 in liver cancer and NASH, plus three additional indications for CF101 and CF602 in Rheumatoid Arthritis, Psoriasis and Sexual Dysfunction

PETACH TIKVA, Israel, Nov. 27, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

Clinical Development Program and Corporate Highlights Include:

Published: 30 November 2015
Written by Editor
AMEX   Financial Results   Up on News  
Read more: Can-Fite BioPharma Ltd ( CANF )

Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer’s Disease Models

Data Strengthens Pipeline Including Sigma-1 and Muscarinic Compound ANAVEX 2-73

NEW YORK, Nov. 30, 2015 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease (AD), other central nervous system (CNS) diseases, pain and various types of cancer, announced today the publication of further data for ANAVEX 3-71 (formerly AF710B) in the peer-reviewed scientific journal Neurodegenerative Diseases.  The ANAVEX 3-71 data provides evidence for a positive, more upstream effect on reducing synaptic loss, amyloid and tau pathologies, and neuroinflammation, which is potentially beneficial for the treatment of Alzheimer’s and other neurological diseases.  ANAVEX 3-71 is part of the Company’s pipeline including ANAVEX 2-73 targeting sigma-1 and muscarinic receptors.

Published: 30 November 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Anavex Life Sciences Corp ( AVXL )

Aduro Biotech Confirms All Clinical Trials Continue Unaltered and as Planned

Management to Host Conference Call Tomorrow at 5 am PST

BERKELEY, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO) today announced that it will hold a conference call tomorrow November 25, 2015 at 5:00 am Pacific Standard Time. To participate in the conference call, please dial (855) 283-3941 (domestic) or (330) 863-3274 (international) and refer to conference ID 90656408. Live audio of the conference call will be simultaneously webcast and will be available to members of the news media, investors and the general public under the Investors section of the company's website at www.aduro.com.

Published: 25 November 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Aduro Biotech Inc ( ADRO )

Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned

VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (“Aurinia” or the “Company”) has announced today that the independent Data and Safety Monitoring Board (“DSMB”) for the Company's Phase 2b lupus nephritis study, known as AURA-LV, has completed its third pre-planned safety review of patients enrolled in the study and recommended continuation of the trial without any modifications. The AURA-LV DSMB has been established according to the FDA Guidance for Clinical Trial Sponsors and is guided by its charter. Aurinia remains blinded to the actual safety and efficacy results.

Published: 24 November 2015
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Aurinia Pharmaceuticals Inc ( AUP / AUPH )

Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement

QUEBEC CITY, Nov. 24, 2015 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ.TO ) (the "Company") announced today that the remaining 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series B Common Share Purchase Warrants (the "Series B Warrants") subject to the previously disclosed November 1, 2015 agreement were exercised on November 23, 2015, which will result in the issuance of 365,518 additional Common Shares.  After giving effect to the issuance of such shares, there will be approximately 6.9 million Common Shares issued and outstanding. 

Published: 24 November 2015
Written by Editor
TSX   Nasdaq  
Read more: Aeterna Zentaris Inc ( AEZ / AEZS )
  1. Novocure Limited ( NVCR )
  2. KaloBios Pharmaceuticals Inc ( KBIO )
  3. Novavax Inc ( NVAX )
  4. Ocera Therapeutics Inc ( OCRX )
  5. Ceapro Inc ( CZO )